Mike Foote

@MikeFooteMD

GI medical oncologist @MSKCancerCenter | Translational Scientist in @ldiaz1971 lab

Joined June 2010

349 Following 874 Followers 881 Posts

Latest posts 5

Pinned post

Mike Foote @MikeFooteMD Apr 27, 2025

New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz)
•100 % cCR in 49 rectal pts
•65 % cCR across 10 other cancers (n=54)
•Safe + all non-CR/recurs salvaged.
=Use IO in NA for MMR-d tumors!

nejm.org/doi/full/10.10…

www.nejm.org Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

Mike Foote @MikeFooteMD Oct 18, 2025

Father and son enjoying #ESMO25 in Berlin!!

Mike Foote @MikeFooteMD Jun 25, 2025

Very excited about our work with 60+ collaborators across the world to define algorithms for management of patients with peritoneal disease! acsjournals.onlinelibrary.wiley.com/doi/abs/10.100…

acsjournals.onlinelibrary.wiley.com Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal... The 2018 Chicago Consensus guidelines for the management of appendix tumors with and without peritoneal involvement have been updated by modified Delphi consensus and supplemented with broad narrat...

Dr. Cathy Eng Verified account @CathyEngMD Jun 25, 2025

Part 1: Consensus guideline for the management of patients with appendiceal tumors: Appendiceal tumors without peritoneal involvement - Godfrey - 2025 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @DeepaMagge @kturaga @ArdamanShergil1 @MikeFooteMD @JournalCancer @appendix #cancer #raretumors

View quoted post on X

Mike Foote @MikeFooteMD Jun 12, 2025

So excited for Benoit Rousseau’s paper in Cancer Cell describing mutagenic chemo combinations to make cold tumors hot!

cell.com/cancer-cell/ab…

www.cell.com Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental... Rousseau et al. show that tailored mutagenic chemical treatment induces a mismatch repair deficient genotype by epigenetic Msh2 silencing leading to potent immune response in immunoresistant tumor...

Mike Foote @MikeFooteMD Feb 25, 2025

Fascinating study by Benoit Rousseau and @ldiaz1971 examining the duration of immune checkpoint blockade in MMRD early stage tumors. Six months seems to be the magic number for complete response rate!

NEJM Verified account @NEJM Feb 21, 2025

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: nej.md/3EXiEpe

View quoted post on X